IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a yea...
Main Authors: | Anthony M. Battram, Mireia Bachiller, Victor Lopez, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/14/3534 |
Similar Items
-
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
by: Deming Duan, et al.
Published: (2021-03-01) -
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01) -
Heterodimeric IL-15 in Cancer Immunotherapy
by: Cristina Bergamaschi, et al.
Published: (2021-02-01) -
NK Cell IL-10 Production Requires IL-15 and IL-10 Driven STAT3 Activation
by: Sarah E. Clark, et al.
Published: (2019-09-01) -
104 BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7
by: Anthony Battram, et al.
Published: (2020-11-01)